N-Acetyltransferase 2 (NAT2) Acetylator Status among Systemic Lupus Erythematosus Patients from A Tuberculosis Endemic Area in Bandung, Indonesia

Laniyati Hamijoyo, Sasfia Candrianita, Ika Agus Rini, Endang Sutedja, Budi Setiabudiawan, Edhyana Sahiratmadja

Abstract


BACKGROUND: Systemic lupus erythematosus (SLE) patients living in Indonesia are prone to tuberculosis (TB) infection, since this country ranks second globally for TB prevalence. Isoniazid, an anti-tuberculosis (TB) drug, is metabolized by enzyme N-acetyltransferase 2 (NAT2) that is encoded by NAT2 gene. NAT2 haplotype, referring as acetylator status, may predispose as genetic factor in SLE development or complicate SLE therapy. This study explored the NAT2 haplotypes and acetylator status among SLE patients living in a TB endemic area.

METHODS: Genomic DNA of 260 registered SLE patients at The Rheumatology Clinic of Dr. Hasan Sadikin General Hospital, Bandung, Indonesia were isolated. NAT2 gene was amplified and sequenced, then NAT2 haplotypes and the acetylator status among SLE patients with or without TB history were determined and presented.

RESULTS: Most of SLE patients registered were female (n=250; 96.2%). The median age of patients when SLE was diagnosed for the first time was 27 years old (8-69 years), with organ involvement predominantly in musculoskeletal (80.8%) and mucocutaneous (73.1%). TB history, mostly pulmonary TB, was present in 23.1% of SLE patients of whom TB was diagnosed before SLE (10.4%) or after SLE (10.7%) or both before and after SLE (2%). The acetylator status was mostly intermediate (61.5%) with the NAT2*4/*6B was the most prevalent haplotype (25.8%).

CONCLUSION: There is a high number of intermediate and low acetylator status among SLE patients. Since these SLE patients live in TB endemic area, the NAT2 acetylator status determination among SLE patients before starting TB therapy may have clinical benefit to decrease a possible drug induced liver injury, and this warrants further study.

KEYWORDS: NAT2, acetylator, systemic lupus erythematosus, tuberculosis


Full Text:

PDF

References


Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol. 2012; 24: 651-7, CrossRef.

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016; 2: 16039, CrossRef.

Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet. 2009; 10: 285-90, CrossRef.

Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol. 2004; 22: 157-66, CrossRef.

Rajasekaran M, Abirami S, Chen C. Effects of single nucleotide polymorphisms on human N-acetyltransferase 2 structureand dynamics by molecular dynamics simulation. PLoS ONE. 2011; 6: e25801, CrossRef.

Unissa AN, Sukumar S, Hanna LE. The role of N-acetyltransferases on isoniazid resistance from mycobacterium tuberculosis and human: an in silico approach. Tuberc Respir Dis. 2017; 80: 255-64, CrossRef.

Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. ArylamineNacetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS ONE.2011; 6: e18507, CrossRef.

Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2012; 13: 31-41, CrossRef.

Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, et al. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population. Lupus. 2009; 18: 630-8, CrossRef.

Cooper GS, Treadwell EL, Dooley MA, St Clair EW, Gilkeson GS, Taylor JA. N-acetyl transferase genotypes in relation to risk of developing systemic lupus erythematosus. J Rheumatol. 2004; 31: 76-80, PMID.

World Health Organization. Global Tuberculosis Report 2017. WHO Report 2017. Geneva: WHO; 2017, article.

Anić F, Zuvić-Butorac M, Stimac D, Novak S. New classification criteria for systemic lupus erythematosus correlate with disease activity. Croat Med J. 2014; 55: 514-9, CrossRef.

Sahiratmadja E, Penggoam S, Maskoen AM, Pramono AA, Aryani D, Rahayu NS, et al. Distribution of rs1801279 and rs1799930 polymorphisms in NAT2 gene among population in Kupang, Nusa Tenggara Timur, Indonesia. Indones Biomed J. 2018; 10: 56-61, CrossRef.

Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016; 12: 716-30, CrossRef.

dos Santos EC, Pinto AC, Klumb EM, Macedo JM. Polymorphisms in NAT2 (N-acetyltransferase 2) gene in patients with systemic lupus erythematosus. Rev Bras Reumatol Engl Ed. 2016; 56: 521-9, CrossRef.

Wattanapokayakit S, Mushiroda T, Yanai H, Wichukchinda N, Chuchottawon C, Nedsuwan S, et al. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. Int J Tuberc Lung Dis. 2016; 20: 1364-9, CrossRef.

Zabost A, Brzezińska S, Kozińska M, Błachnio M, Jagodziński J, Zwolska Z, et al. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients. Biomed Res Int. 2013; 2013: 853602, CrossRef.

Yuliwulandari R, Susilowati RW, Wicaksono BD, Viyati K, Prayuni K, Razari I, et al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet. 2016; 61: 533-7, CrossRef.

Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011; 34: 357-74, CrossRef.

Zschieschang P, Hiepe F, Gromnica-Ihle E, Roots I, Cascorbi I. Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics. 2002; 12: 559-63,

Rychlik-Sych M, Skretkowicz J, Gawrońska-Szklarz B, Górnik W, Sysa-Jedrzejowska A, Skretkowicz-Szarmach K. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep. 2006; 58: 22-9, PMID.

Ghosh K, Patwardhan M, Pradhan V. Mycobacterium tuberculosis infection precipitates SLE in patients from endemic areas. Rheumatol Int. 2009; 29: 1047-50, CrossRef.

Jung JY, Suh CH. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med. 2017; 32: 429-38, CrossRef.

Lin YC, Liang SJ, Liu YH, Hsu WH, Shih CM, Sung FC, et al. Tuberculosis as a risk factor for systemic lupus erythematosus: results of a nation wide study in Taiwan. Rheumatol Int. 2012; 32: 1669-73, CrossRef.

Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002; 31: 296-300, CrossRef.

Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013; 69: 1091-101, CrossRef.




DOI: https://doi.org/10.18585/inabj.v11i2.553

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute